Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group.
The management of aggressive fibromatosis (AF) is problematic, and few options are available to patients unsuitable for surgery and resistant to external-beam radiation therapy (EBRT). We report on two patients with fast-growing recurrences of AF resistant to EBRT who obtained protracted clinical benefits with (90)Y-DOTATOC. (90)Y-DOTATOC should be further investigated in this setting.
De Pas
T
T
Division of Medical Oncology, European of Oncology, Via Ripamonti, Milan, Italy. tommaso.de-pas@ieo.it
Bodei
L
L
Pelosi
G
G
De Braud
F
F
Villa
G
G
Capanna
R
R
Paganelli
G
G
D000328:Adult; D005260:Female; D018222:Desmoid Tumors / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D018714:Radiotherapy, Adjuvant / Q000379:methods*; D018000:Receptors, Peptide / Q000627:therapeutic use*; D012008:Recurrence; D012189:Retrospective Studies
D019275:Radiopharmaceuticals; D018000:Receptors, Peptide; D015282:Octreotide; C106246:Edotreotide